| A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19 DR Boulware, MF Pullen, AS Bangdiwala, KA Pastick, SM Lofgren, ... New England journal of medicine 383 (6), 517-525, 2020 | 1558 | 2020 |
| Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial CP Skipper, KA Pastick, NW Engen, AS Bangdiwala, M Abassi, ... Annals of internal medicine 173 (8), 623-631, 2020 | 640 | 2020 |
| Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19) KA Pastick, EC Okafor, F Wang, SM Lofgren, CP Skipper, MR Nicol, ... Open forum infectious diseases 7 (4), ofaa130, 2020 | 236 | 2020 |
| Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial R Rajasingham, AS Bangdiwala, MR Nicol, CP Skipper, KA Pastick, ... Clinical Infectious Diseases 72 (11), e835-e843, 2021 | 167 | 2021 |
| Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial J Rhein, KH Hullsiek, L Tugume, E Nuwagira, E Mpoza, EE Evans, ... The Lancet infectious diseases 19 (8), 843-851, 2019 | 100 | 2019 |
| Pharmacogenomics of COVID-19 therapies T Takahashi, JA Luzum, MR Nicol, PA Jacobson NPJ genomic medicine 5 (1), 35, 2020 | 86 | 2020 |
| RGS inhibition at Gαi2 selectively potentiates 5-HT1A–mediated antidepressant effects JN Talbot, EM Jutkiewicz, SM Graves, CF Clemans, MR Nicol, ... Proceedings of the National Academy of Sciences 107 (24), 11086-11091, 2010 | 76 | 2010 |
| Finding the dose for hydroxychloroquine prophylaxis for COVID‐19: the desperate search for effectiveness M Al‐Kofahi, P Jacobson, DR Boulware, A Matas, R Kandaswamy, ... Clinical Pharmacology & Therapeutics 108 (4), 766-769, 2020 | 66 | 2020 |
| Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19 SM Lofgren, MR Nicol, AS Bangdiwala, KA Pastick, EC Okafor, ... Open forum infectious diseases 7 (11), ofaa500, 2020 | 58 | 2020 |
| Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention MR Nicol, Y Fedoriw, M Mathews, HMA Prince, KB Patterson, E Geller, ... The Journal of Clinical Pharmacology 54 (5), 574-583, 2014 | 56 | 2014 |
| A systematic review of treatment and outcomes of pregnant women with COVID-19—a call for clinical trials KA Pastick, MR Nicol, E Smyth, R Zash, DR Boulware, R Rajasingham, ... Open forum infectious diseases 7 (9), ofaa350, 2020 | 42 | 2020 |
| Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B CP Skipper, M Atukunda, A Stadelman, NW Engen, AS Bangdiwala, ... Antimicrobial agents and chemotherapy 64 (10), 10.1128/aac. 00838-20, 2020 | 41 | 2020 |
| Pharmacokinetics and pharmacological properties of chloroquine and hydroxychloroquine in the context of COVID‐19 infection MR Nicol, A Joshi, ML Rizk, PE Sabato, RM Savic, D Wesche, JH Zheng, ... Clinical Pharmacology & Therapeutics 108 (6), 1135-1149, 2020 | 39 | 2020 |
| Pharmacologic opportunities for HIV prevention MR Nicol, ADM Kashuba Clinical Pharmacology & Therapeutics 88 (5), 598-609, 2010 | 38 | 2010 |
| HIV pre-exposure prophylaxis trials: the road to success. MR Nicol, JL Adams, ADM Kashuba | 32* | 2013 |
| Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women JB Dumond, MR Nicol, RN Kendrick, SM Garonzik, KB Patterson, ... Clinical pharmacokinetics 51, 809-822, 2012 | 29 | 2012 |
| Review of Real‐World Implementation Data on Emtricitabine‐Tenofovir Disoproxil Fumarate as HIV Pre‐exposure Prophylaxis in the United States JL Adams, K Shelley, MR Nicol Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (4 …, 2019 | 27 | 2019 |
| Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model S Chesdachai, R Rajasingham, MR Nicol, DB Meya, F Bongomin, ... Open forum infectious diseases 6 (10), ofz369, 2019 | 25 | 2019 |
| Models for predicting effective HIV chemoprevention in women MR Nicol, CW Emerson, HMA Prince, JAE Nelson, Y Fedoriw, C Sykes, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 68 (4), 369-376, 2015 | 21 | 2015 |
| Cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tract CG Thompson, A Sedykh, MR Nicol, E Muratov, D Fourches, A Tropsha, ... AIDS research and human retroviruses 30 (11), 1058-1064, 2014 | 19 | 2014 |
David R BoulwareProfessor of Medicine, University of MinnesotaVerified email at Umn.edu
